|Bid||23.54 x 1000|
|Ask||23.58 x 1100|
|Day's Range||23.22 - 25.75|
|52 Week Range||6.80 - 28.09|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Moderna has emerged as a strong competitor in the race for a coronavirus vaccine. But Moderna stock remains on a wild ride in 2020 as the need for a Covid-19 vaccine grows.
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
Messenger RNA (mRNA) coronavirus vaccine candidates now appear to be batting two for two. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced great interim efficacy results for their experimental mRNA COVID-19 vaccine last week. Are there other biotech stocks with mRNA vaccine programs that could also be winners?